Header

UZH-Logo

Maintenance Infos

Use of oseltamivir in lung transplant recipients with suspected or proven influenza infection: a 1-year observational study of outcomes and safety


Jungo, Christoph; Russmann, Stefan; Benden, Christian; Schuurmans, Macé M (2019). Use of oseltamivir in lung transplant recipients with suspected or proven influenza infection: a 1-year observational study of outcomes and safety. Antiviral Therapy, 24(7):495-503.

Abstract

BACKGROUND:

Influenza virus infections in lung transplant recipients (LTRs) have an increased risk of unfavorable outcomes. Early initiation of treatment is associated with improved outcomes. In clinical practice, empiric oseltamivir treatment is therefore commonly started prior to diagnostic microbiological confirmation. There is limited data on the patient characteristics, outcomes and safety of this practice. This study investigated outcomes and safety of this preemptive treatment strategy using oseltamivir.
METHODS:

Descriptive analysis of LTRs who received oseltamivir for ≥2 days for suspected influenza infection between 07-2011 and 06-2012. Analyses were based on data from electronic medical records and our standardized LTR database with prospective documentation of clinical information including medication, laboratory and radiological results, outcomes and adverse events.
RESULTS:

We included 133 patients with a total of 261 oseltamivir treatment episodes (87.4% as outpatients). Median duration of oseltamivir treatment was 4 days (range 2 to 67), and 98.5% had concomitant antibiotic pharmacotherapy. Indications for oseltamivir included acute respiratory infection (66.7%), non-distinctive inflammatory reaction (51.3%), and influenza-like illness (2.7%). Influenza virus infection was confirmed by PCR in only 7%. Rhinovirus was the most frequent pathogen detected (14.9%). We discovered a wide range of adverse events but none occurred in >5%, and most were mild and of questionable causal relationship to oseltamivir administration.
CONCLUSIONS:

This non-controlled retrospective analysis suggests that the preemptive use of oseltamivir for respiratory tract infections pending microbiological results is safe in LTRs.

Abstract

BACKGROUND:

Influenza virus infections in lung transplant recipients (LTRs) have an increased risk of unfavorable outcomes. Early initiation of treatment is associated with improved outcomes. In clinical practice, empiric oseltamivir treatment is therefore commonly started prior to diagnostic microbiological confirmation. There is limited data on the patient characteristics, outcomes and safety of this practice. This study investigated outcomes and safety of this preemptive treatment strategy using oseltamivir.
METHODS:

Descriptive analysis of LTRs who received oseltamivir for ≥2 days for suspected influenza infection between 07-2011 and 06-2012. Analyses were based on data from electronic medical records and our standardized LTR database with prospective documentation of clinical information including medication, laboratory and radiological results, outcomes and adverse events.
RESULTS:

We included 133 patients with a total of 261 oseltamivir treatment episodes (87.4% as outpatients). Median duration of oseltamivir treatment was 4 days (range 2 to 67), and 98.5% had concomitant antibiotic pharmacotherapy. Indications for oseltamivir included acute respiratory infection (66.7%), non-distinctive inflammatory reaction (51.3%), and influenza-like illness (2.7%). Influenza virus infection was confirmed by PCR in only 7%. Rhinovirus was the most frequent pathogen detected (14.9%). We discovered a wide range of adverse events but none occurred in >5%, and most were mild and of questionable causal relationship to oseltamivir administration.
CONCLUSIONS:

This non-controlled retrospective analysis suggests that the preemptive use of oseltamivir for respiratory tract infections pending microbiological results is safe in LTRs.

Statistics

Citations

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Pneumology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Pharmacology
Health Sciences > Pharmacology (medical)
Health Sciences > Infectious Diseases
Language:English
Date:1 January 2019
Deposited On:15 Jan 2020 10:15
Last Modified:29 Jul 2020 12:52
Publisher:International Medical Press
ISSN:1359-6535
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.3851/imp3320
PubMed ID:31172978

Download

Full text not available from this repository.
View at publisher

Get full-text in a library